Mylan (MYL) Launches Generic Epivir Tabs in Italy, the U.K. (GSK)
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan Inc. (Nasdaq: MYL) says its UK and Italy-based subsidiaries have launched Lamivudine Film Coated Tablets, 150 mg and 300 mg. This product is the generic version of GlaxoSmithKline's (NYSE: GSK) Epivir Tablets, indicated as part of antiretroviral (ARV) combination therapy for the treatment of HIV-infected adults and children. This is the first generic HIV treatment to be available from Mylan in Europe.
Mylan CEO Heather Bresch commented: "As one of the world's leading providers of affordable ARVs, Mylan has a long history of contributing to the fight against HIV/AIDS across the developing world. We are excited that we can now bring our passion and experience in this important area to the European markets with the launch of Lamivudine, further delivering on our commitment to providing high quality and affordable medicines to patients around the world."
Mylan CEO Heather Bresch commented: "As one of the world's leading providers of affordable ARVs, Mylan has a long history of contributing to the fight against HIV/AIDS across the developing world. We are excited that we can now bring our passion and experience in this important area to the European markets with the launch of Lamivudine, further delivering on our commitment to providing high quality and affordable medicines to patients around the world."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- FDA clears Implantica's RefluxStop implant for U.S. market
- Simmons Bank chief data officer Lisa Hunter to retire
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
